Immunotherapy trials in oncology have shown tremendous promise and may represent the most promising cancer treatment approach in the past 50 years. New scientific breakthroughs always come with a learning curve. It’s no different with cancer immunotherapy research. To mitigate risk, it’s critical for sponsors and investigators — and everyone else working on your immunotherapy trial — to understand how the immune system responds to cancer treatments.
This immuno-oncology guide provides eight recommendations to keep your immuno-oncology study on track and was developed from our hands-on experience managing complex cancer immunotherapy studies since 2008.
The content in this guide is designed for CMOs, VPs and Directors of Clinical Development, the clinical operations team and any others involved in designing and managing immuno-oncology studies.
A GUIDE FOR CHOOSING THE RIGHT IMMUNO-ONCOLOGY CRO
Please share your contact information to download the guide. We promise to keep your information private.